Effectiveness of Rituximab, Belimumab, and Thrombopoietin Receptor Agonists in Refractory Immune Thrombocytopenia Associated With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Ryuichi Ohta, Yoshinori Ryu, Kunihiro Ichinose · 2025
Read Effectiveness of Rituximab, Belimumab, and Thrombopoietin Receptor Agonists in Refractory Immune Thrombocytopenia Associated With Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis by Ryuichi Ohta, Yoshinori Ryu, Kunihiro Ichinose (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12799297.txt.
Description
Ohta, Ryu, and Ichinose pool proof on hard-to-treat low platelets in lupus. Low platelets are a common and grave sign in lupus. Some patients stay low despite standard drug care. Three targeted drugs have been used in small studies.
The team searched for all studies of those three drugs in lupus. Each study covered adults with proven lupus and stubborn low platelets. Pooled rates showed how often platelets rose with each drug. Harms and dose facts were also weighed in the pool. Clear pooled proof can guide doctors in rare, tough cases. The review sets a base for larger trials.
Catalog record
| CREATOR | Ryuichi Ohta, Yoshinori Ryu, Kunihiro Ichinose |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |